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A B S T R A C T
Background
Most disabling strokes are due to blockage of a large artery in the brain by a blood clot. Prompt removal of the clot with intra-arterial
thrombolytic drugs or mechanical devices, or both, can restore blood flow before major brain damage has occurred, leading to improved
recovery. However, these so-called percutaneous vascular interventions can cause bleeding in the brain.
Objectives
To assess the safety and efficacy of percutaneous vascular interventions in patients with acute ischaemic stroke.
Search methods
We searched the Trials Registers of the Cochrane Stroke Group and Cochrane Peripheral Vascular Diseases Group (last searched May
2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 5), MEDLINE (1980 to
May 2010), EMBASE (1980 to May 2010) and eight additional databases. We also searched trials registers, screened reference lists,
contacted researchers and equipment manufacturers, and handsearched journals and conference proceedings.
Selection criteria
Randomised, controlled and unconfounded trials of any percutaneous vascular intervention compared with control in patients with
definite ischaemic stroke.
Data collection and analysis
Two review authors applied the inclusion criteria, extracted data and assessed trial quality.We obtained both published and unpublished
data if available
Main results
We included four trials involving 350 patients. Not all trials contributed data to each outcome. The trials tested either intra-arterial
urokinase or recombinant pro-urokinase versus an open control. One trial used guidewire-mediated clot disruption in some patients
randomised to the intervention group. Most data came from trials that started treatment up to six hours after stroke; one small trial
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started treatment up to a median of 12.5 hours after stroke. Most data came from trials of middle cerebral artery territory infarction.
Compared with non-thrombolytic standard medical treatment, the intervention administered up to six hours after ischaemic stroke
significantly increased the proportion of patients with favourable outcome (modified Rankin 0 to 2) three months after stroke (relative
risk (RR) 1.47, 95% confidence interval (CI) 1.07 to 2.02). The intervention also significantly increased the risk of symptomatic
intracranial haemorrhage within 24 hours of treatment (RR 3.85, 95% CI 0.91 to 16.36). There was no significant heterogeneity
between the included trials.
Authors’ conclusions
Overall, intervention results in a significant increase in the proportion of patients with a favourable outcome, despite a significant
increase in intracranial haemorrhage. Further trials are needed to confirm or refute these findings and, given the cost and practical
difficulties, to establish whether percutaneous techniques are feasible and cost effective in wider clinical practice.
P L A I N L A N G U A G E S U M M A R Y
Percutaneous vascular interventions for acute ischaemic stroke
The majority of disabling strokes are due to blockage of a large artery in the brain by a blood clot. For these patients, the most intuitive
means of treatment is removal of the blockage by either injecting clot-dissolving (thrombolytic) drugs directly into the clot or removal
of the clot using a mechanical device, or both. Prompt treatment can restore blood flow before major brain damage has occurred,
leading to a good recovery. However, these treatments can also cause bleeding in the brain with poorer outcomes. This review of four
trials involving 350 participants indicated that this form of treatment can remove large artery blood clots and improve the chances of
good recovery despite an increased risk of bleeding in the brain. Long term risk of death is unaffected. However, it is still not clear what
the time window is within which treatment is beneficial, what types of arterial blockage are most likely to respond, whether mechanical
devices are effective, and whether any of these treatments are better than standard intravenous thrombolytic drugs. More information
is needed from forthcoming randomised trials to answer these questions.
B A C K G R O U N D
Acute ischaemic stroke is a major cause of death and disability
worldwide (Warlow 2003). The usual mechanisms are cerebral
thrombosis and embolism. The prompt administration of intra-
venous thrombolytic drugs to selected patients has been shown to
be beneficial (Wardlaw 2009) and is now used as routine medical
treatment in those patients. The rapidly developing field of in-
terventional radiology currently offers a variety of alternative ap-
proaches to recanalisation in acute ischaemic stroke. Case series
have provided some feasibility and safety data (Brekenfeld 2005;
Nedeltchev2006) but they cannot provide evidence of efficacy.We
therefore aimed to perform a systematic review of all randomised
controlled trials (RCTs) in this field.
O B J E C T I V E S
The objective of this review was to assess whether percutaneous
vascular interventions plus medical treatment are superior to med-
ical treatment alone for brain infarction.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials comparing percutaneous vascular in-
terventions plus medical treatment to medical treatment alone in
patients with acute ischaemic stroke. Intravenous thrombolytic
treatment was permissible only when the same intravenous throm-
bolytic treatment was given to both the intervention group and
the control group.
Types of participants
Patients with a definite acute ischaemic stroke (that is comput-
erised tomography (CT) or magnetic resonance imaging (MRI)
must have excluded cerebral haemorrhage).
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Types of interventions
All percutaneous arterial endovascular techniques aimed at revas-
cularisation in acute ischaemic stroke, including but not confined
to:
• angiojet aspiration;
• laser recanalisation;
• thromboaspiration (retrieval devices);
• angioplasty;
• mechanical fragmentation of the thrombus;
• implantation of stents;
• intra-arterial thrombolysis;
• intra-arterial sonothrombolysis.
All types of medical treatment could be given in addition to the
percutaneous interventions. Intravenous thrombolytic treatment
was permissible only when the same intravenous thrombolytic
treatment was also given to the control group.
Type of comparison therapy
The comparison therapy was routine medical treatment. Intra-
venous thrombolytic treatment was permissible only when the
same intravenous thrombolytic treatment was also given to the
intervention group.
Types of outcome measures
Primary outcome measure
Favourable functional outcome at the end of the scheduled follow-
up period defined as a modified Rankin scale score of 0 to 2. Given
that some prefer a definition of ’favourable outcome’ as a score
of 0 to 1 (NINDS 1995), we also sought data on the number of
patients in each individual modified Rankin scale category. If the
modified Rankin scale score was not reported, we used the trial’s
definition of functional outcome.
Secondary outcome measures
1. Deaths from all causes, both: (a) during the acute phase, i.e.
first seven to 10 days, and (b) at the end of scheduled follow-up.
2. All intracranial haemorrhages and symptomatic intracranial
haemorrhage within the acute phase (non-fatal or fatal). We
defined symptomatic intracranial haemorrhage according to both
the National Institute of Neurological Disorders and Stroke
(NINDS) study (NINDS 1995) and European Cooperative
Acute Stroke Study (ECASS) (Hacke 1995) criteria. When
symptomatic intracranial haemorrhage was not reported
according to these criteria, we considered using the trial’s
definition.
3. Degree of revascularisation, according to Higashida
(Higashida 2003) and using the AOL score and the TIMI score
(Khatri 2005).
4. Neurological status at end of follow-up.
5. Impairments at end of follow-up, e.g. Barthel Index score.
6. Major extracranial haemorrhage in the acute phase.
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module.
1. We searched the Cochrane Stroke Group Trials Register,
which was last searched by the Managing Editor in May 2010.
We also searched the Trials Register of the Cochrane Peripheral
Vascular Diseases Group (last searched May 2010).
2. In addition, we searched the following electronic databases
from 1980 (the earliest publications in this field date from the
1980s). We adapted the MEDLINE search strategy for the other
databases.
i) Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2010, Issue 5).
ii) MEDLINE (from 1980 to May 2010) (Appendix 1).
iii) EMBASE (from 1980 to May 2010) (Appendix 2).
iv) Science Citation Index (from 1980 to May 2010).
v) ISI Proceedings (from 1990 to May 2010).
vi) LILACS (Latin American and Caribbean Health
Sciences Literature,1982 to May 2010).
vii) ACP journal club (http://www.acpjc.org) (last
searched May 2010).
viii) Database of Abstracts of Reviews of Effects (DARE) (
http://www.crd.york.ac.uk/crdweb) (last searched May 2010).
ix) ProQuest Dissertations & Theses (PQDT) (http://
proquest.umi.com/login) (last searched May 2010).
x) British Library Theses Service (http://www.bl.uk/
britishthesis) (last searched May 2010).
xi) National Research Register Archive (http://
portal.nihr.ac.uk/Pages/NRRArchive.aspx) (last searched May
2010).
3. In an effort to identify further published, unpublished,
ongoing and planned trials we:
i) screened reference lists of relevant trials;
ii) contacted the manufacturers of any interventional
radiological equipment included in the review. We received
replies from CoAxia Inc, phenox GmbH, EKOS Corporation,
Boston Scientific, and Concentric Medical Inc;
iii) contacted professional organisations in neuroradiology
and interventional radiology and authors and researchers active
in the field. We received replies from Raul Nogueira MD,
Takashi Inoue MD, Malcolm McLeod PhD, Helmi L Lutsep
MD, Alfonso Ciccone MD, Peter Rothwell PhD, and Chelsea
Kidwell MD. We also received replies from the American Society
of Neuroradiology and the British Society of Neuroradiology;
3Percutaneous vascular interventions for acute ischaemic stroke (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
iv) handsearched the following journals from first
available date, except those issues already searched on behalf of
The Cochrane Collaboration and submitted to CENTRAL (
http://apps1.jhsph.edu/cochrane/masterlist.asp):
a) American Journal of Neuroradiology (1990 to
2010),
b) Brain (1990 to 2010),
c) Neuroradiology (1990 to 2010),
d) Stroke (1990 to 2010);
v) searched the following ongoing trials registers (last
searched May 2010):
a) Stroke Trials Registry (http://
www.strokecenter.org/trials),
b) ClinicalTrials.gov (http://www.clinicaltrials.gov),
c) Current Controlled Trials (http://
www.controlled-trials.com);
vi) searched conference proceedings for the World
Federation of Interventional and Therapeutic Neuroradiology
(2009);
vii) searched Google Scholar.
We searched for trials in all languages and arranged for translation
of trial reports published in languages other then English.
Data collection and analysis
Selection of studies
Two review authors (KOR and EB) independently screened titles
and abstracts of references identified by the searches. We obtained
full paper copies of those trial reports which, from the title and
abstract, appeared to be eligible for inclusion. The same two re-
view authors then independently assessed these for inclusion. The
review authors resolved any disagreements by discussion, with in-
put from a third review author (PK) when needed. When a trial
was excluded, we kept a record of both the report and the reason
for exclusion.
Quality assessment
Two review authors (KOR and EB) independently performed
quality assessment of reports of eligible trials; they resolved any dis-
agreements by discussion. We used the following criteria to assess
the quality of reports of eligible trials according to section 8.5.3
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2008):
1. adequate sequence generation;
2. allocation concealment;
3. blinding: in trials of percutaneous vascular interventions it
is not possible to blind either the participants or those providing
the interventions. However, outcome assessors can be blinded. In
this review, we defined blinding as ’yes’, ’no’, or ’unclear’ as it
pertained to blinding of outcome assessors;
4. incomplete outcome data addressed: we considered
intention-to-treat analysis (ITT) adequate when (a) patients were
analysed in the groups to which they were randomised regardless
of what treatment they received, and (b) when the numbers of
patients lost to follow-up and the associated reasons were
reported;
5. free of selective reporting;
6. free of other bias.
We used the above criteria to construct a risk of bias table for each
eligible trial, as outlined in section 8.6 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2008).
Data extraction
Two review authors (KOR and EB) independently extracted data
from the report of each eligible trial on a specially designed data
extraction form. The review authors were not blinded to journal
or institution. We extracted the following data from each report:
• diagnostic criteria used for acute ischaemic stroke, including
whether magnetic resonance imaging (MRI) diffusion/perfusion
mismatch, computerised tomography (CT) angiography, or CT
perfusion were used to identify eligible patients;
• time interval from onset to randomisation;
• time to actual delivery of percutaneous vascular therapy
(not start of procedure);
• numbers of patients in each treatment group with outcome
events;
• modality of percutaneous vascular intervention used;
• precise form of comparison therapy used.
One review author (KOR) entered the data into the Cochrane
Review Manager software, RevMan 5.0 (RevMan 2008). These
were checked by another review author (CW) against the hard
copy data extraction forms to correct any clerical data entry errors.
When any relevant data were missing from the available publica-
tions, we contacted the principal investigators or industrial spon-
sors concerned.
Data synthesis
We analysed the data using the Cochrane Review Manager soft-
ware, RevMan 5.0 (RevMan 2008). Two review authors (KOR
and CW) independently conducted data analysis and resolved any
disagreements by discussion. The appropriate statistical analysis
was a binary logistic regression. We selected the Mantel-Haenszel
method in view of both the relatively small size of the included
trials and the relatively low event rates. We also aimed to carry out
an ordinal logistic regression.
We estimated heterogeneity between trials’ results using the I
2 statistic (Higgins 2002). There was no statistically significant
heterogeneity between the trials included in this review and we
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therefore deemed a fixed-effect meta-analysis appropriate.We per-
formed subgroup analyses using the methodology described by
Deeks et al (Deeks 2001) as recommended in section 18.4.5 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2008).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
We included four trials (PROACT 1 1998; PROACT 2 1999;
AUST 2005; MELT 2007) in which a total of 356 patients were
randomised. Data on 350 patients were available for inclusion in
the review. This is because functional outcome data for six patients
who were randomised but not treated were not included in the
PROACT11998 trial publication andwere otherwise unavailable.
Types and severities of strokes included
Three trials (PROACT 1 1998; PROACT 2 1999; MELT 2007)
screened patients with middle cerebral artery territory strokes.
AUST 2005 screened patients with posterior circulation strokes.
See Characteristics of included studies table.
Age and gender of included patients
The mean age of patients in the treatment group in PROACT 1
1998 was 66 years, and in the control group 69 years. The mean
age of patients in the treatment and control groups in PROACT
2 1999 and AUST 2005 was 64 years. The mean age of patients
in the treatment and control groups in MELT 2007 was 67 years.
Across the four included studies, 124 out of a total of 212 patients
randomised to the treatment groups were men (58%), and 85
out of a total of 138 patients randomised to the control groups
were men (61%). More men than women were randomised to the
treatment groups in the PROACT 1 1998 and PROACT 2 1999
trials (14 out of 24 treatment patients versus 5 out of 14 control
patients in PROACT 1 1998 were men; 70 out of 121 treatment
versus 36 out of 59 control patients in PROACT 2 1999 were
men). In AUST 2005, three out of eight patients in the treatment
group were men, whereas seven out of eight patients in the control
group were men. No gender imbalance was evident between the
treatment and control groups in MELT 2007.
Medical histories
There was little information available regarding the background
medical information for patients in PROACT 1 1998 and MELT
2007. In PROACT2 1999, conventional vascular risk factors were
well balanced among the treatment and control groups, except for
a significant excess of diabetic patients in the control group: 16 of
121 patients in the treatment group versus 18 of 59 patients in
the control group (Chi2 7.7, df = 1, P < 0.005). In AUST 2005,
conventional vascular risk factors were well balanced among the
treatment and control groups.
Mechanism
The predominant mechanisms of stroke in the included studies
were: (1) cardioembolic, (2) carotid atheroembolism, and (3) un-
known. Lacunar infarcts were not excluded. The proportion of
cardiogenic strokes in PROACT 1 1998 was 54% in the treatment
arm and 64% in the control arm, and in PROACT 2 1999 60% in
the treatment arm and 51% in the control arm. The proportion of
cardiogenic strokes was much higher in MELT 2007 (88% in the
treatment arm and 83% in the control arm). In AUST2005, given
the exclusive selection of posterior circulation strokes it can be as-
sumed that the mechanisms were cardioembolic, vertebrobasilar
atheroembolism, or unknown.
Visible infarction on the CT scan at randomisation
In PROACT 1 1998 patients with CT abnormalities that were
consistent with early ischaemia were included, comprising 23 out
of 40 randomised patients. In five of these 23 patients, the area of
CT ischaemia was greater than one-third of the middle cerebral
artery territory. All of these five patients were allocated to the
treatment group and all developed haemorrhagic transformation
within 24 hours. In PROACT 2 1999, patients with hypodense
changes or sulcal effacement involving more than one-third of the
territory of the middle cerebral artery were excluded (ECASS CT
criterion). Early ischaemic changes were present in 125 out of 180
randomised patients, and the ECASS CT criterion was violated in
14 of these 125 patients. Of the 14 cases where the ECASS CT
criterion was violated, 12 were allocated to the treatment group.
Therefore, a total of 17 patients from PROACT 1 1998 and
PROACT 2 1999 were randomised to treatment in violation of
the ECASS CT criterion, representing 8% of the total number of
patients randomised to treatment across the four included studies.
Any bias introduced by this factor would be expected to dilute any
favourable treatment effect and increase the rate of intracerebral
haemorrhage in the treatment group.
Patients were not excluded from AUST 2005 on the basis of base-
line ischaemic CT abnormalities. In MELT 2007 patients with
CT abnormalities consistent with subtle early ischaemia in the
insular cortex, frontal and temporal opercula, or lenticular nuclei
were included. These CT abnormalities were present in 54 out of
a total of 114 randomised patients (47%).
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Time to randomisation
In PROACT 1 1998 and PROACT 2 1999 the protocol specified
randomisation and initiation of treatmentwithin six hours of onset
of symptoms. The time to randomisation in PROACT 1 1998
was unclear. The time to actual delivery of percutaneous vascular
therapy (not start of procedure) in PROACT 1 1998 was a median
5.4 hours for the treatment group and 5.7 hours for the control
group. In PROACT 2 1999 the time to randomisation was a
median 4.7 hours in the treatment group and 5.1 hours in the
control group. In AUST 2005 the onset to treatment time was a
mean 11.8 hours in the treatment group and 12.5 hours in the
control group. In MELT 2007 the onset to randomisation time
was a mean 3.3 hours in the treatment group and 3.4 hours in the
control group.
It was clear that the patients in MELT 2007 were randomised
earlier than the patients in PROACT 1 1998 and PROACT 2
1999. This constituted a potential source of bias towards more
favourable outcome in the MELT 2007 patients compared to the
PROACT 1 1998 and PROACT 2 1999 patients.
Drug, dosage, and means of drug delivery
There were differences between the PROACT trials (PROACT 1
1998; PROACT 2 1999) and MELT 2007 in terms of the dose,
form, andmethod of drug delivery. See Characteristics of included
studies table.
Mechanical clot disruption
Mechanical clot disruption was prohibited by the protocol in
PROACT 1 1998 and PROACT 2 1999 and did not occur in
AUST 2005. In MELT 2007 mechanical clot disruption with a
guidewire was permitted and was performed in 39 patients in the
treatment group.
Concomitant use of antithrombotic treatment
The protocol for concomitant antithrombotic therapy varied from
trial to trial. There was likely to have been an imbalance in the
antithrombotic therapy given to the treatment and control groups
in PROACT 1 1998, where safety concerns prompted an alter-
ation of the concomitant antithrombotic regime during the trial.
Similarly, the MELT 2007 protocol specified that heparin, war-
farin and aspirin should not be given for 24 hours in the treatment
group. In terms of outcome, the direction of any bias introduced
by these imbalances is unknown.
Assessment of outcome
All trials reported mortality data at the end of follow-up. For one
trial (MELT 2007) data were available for deaths in the acute
phase. Assessment of primary functional outcome was by means
of the modified Rankin scale in all four included trials. A potential
source of bias was the fact that PROACT 11998, which comprised
11% of the total number of patients, did not report the outcome
in terms of modified Rankin scale 0 to 2. All four included trials
reported Barthel Index outcome data for activities of daily living.
Three trials (PROACT 1 1998; PROACT 2 1999, MELT 2007)
reported neurological outcome data in the form of the NIHSS.
The method of determination of intracranial haemorrhage was
variable and is listed in the Characteristics of included studies
table.
Two trials reported recanalisation using the TIMI classification
(PROACT 1 1998; PROACT 2 1999): TIMI grade 3 is com-
plete flow in both M1 and M2 divisions of the middle cerebral
artery, TIMI grade 2 is partial flow in either middle cerebral artery
segment. One trial (MELT 2007) reported recanalisation as: (1)
complete, (2) partial and less than 50% in the affected territory,
(3) partial and at least 50% in the affected territory, and (4) no
recanalisation. One trial (AUST 2005) did not pre-specify crite-
ria for judging recanalisation, although recanalisation at day 7 to
10 was a pre-specified secondary outcome. Recanalisation was de-
scribed as either complete or partial.
Risk of bias in included studies
The quality of randomisation in included studies was variable.
Blinding was considered likely to have been adequate in all in-
cluded trials.
While no patients were lost to follow-up in any of the included tri-
als, one trial (PROACT 1 1998) did not report intention-to-treat
analyses and one trial (AUST 2005) did not report pre-specified
secondary outcomes. Such selective reporting clearly conferred a
risk of bias.
Three included trials (PROACT 1 1998; AUST 2005; MELT
2007) were terminated early and consequently suffered from a
lack of statistical power. For details, see Characteristics of included
studies table.
Effects of interventions
Functional outcome at the end of follow-up
For modified Rankin score 0 to 2, data were available for a total
of 310 randomised patients from three trials (PROACT 2 1999;
AUST 2005; MELT 2007). There was an overall significant effect
in favour of treatment (relative risk (RR) 1.47, 95% confidence
interval (CI) 1.07 to 2.02, P = 0.02) with very little between-study
heterogeneity (I2 = 0%, P = 0.47) (Analysis 1.1). For modified
Rankin score 0 to 1, data were available for a total of 350 ran-
domised patients from four trials (PROACT 1 1998; PROACT
2 1999; AUST 2005; MELT 2007). There was an overall highly
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significant effect in favour of treatment (RR 1.73, 95% CI 1.17
to 2.57, P = 0.006) with very little between-study heterogeneity
(I2 = 0%, P = 0.74) (Analysis 1.2).
Deaths from all causes during follow-up
Data were available for a total of 350 randomised patients from
four trials (PROACT 1 1998; PROACT 2 1999; AUST 2005;
MELT 2007). There was no evidence of an effect on death from
all causes in the treatment group (RR 0.89, 95% CI 0.60 to 1.33,
P = 0.58) with very little between-study heterogeneity (I2= 0%, P
= 0.80) (Analysis 2.1).
Deaths from all causes during the acute phase
Data were available for a total of 114 patients from a single trial
(MELT 2007). There was no evidence of an effect on death from
all causes in the acute phase in the treatment group (RR 5.00, 95%
CI 0.25 to 101.89, P = 0.30) (Analysis 2.2).
Symptomatic intracranial haemorrhage during the
first 24 hours
Data were available for a total of 202 randomised patients from
two trials (PROACT 1 1998; PROACT2 1999). There was a non-
significant trend towards excess risk of symptomatic intracerebral
haemorrhage in the treatment group (RR 3.85, 95% CI 0.91 to
16.36, P = 0.07) with very little between-study heterogeneity (I2
= 0%, P = 0.52) (Analysis 3.1).
Symptomatic intracranial haemorrhage at the end of
follow-up
Data were available for a total of 40 randomised patients from a
single trial (PROACT 1 1998). Whilst there was no evidence of
an excess risk of intracerebral haemorrhage in the treatment group
(RR1.08, 95%CI 0.22 to 5.17, P = 0.93), the confidence intervals
were wide and could not exclude the possibility of a substantial
excess (Analysis 3.2).
Recanalisation
TIMI recanalisation data were available for a total of 198 ran-
domised patients from the PROACT 1 1998 and PROACT 2
1999 trials. For TIMI grade 3, there was an overall significant ef-
fect in favour of treatment (RR 8.25, 95% CI 1.63 to 41.90, P
= 0.01) with very little between-study heterogeneity (I2 = 0%, P
= 0.81) (Analysis 4.1). When data for TIMI grade 2 and 3 were
examined there was an overall very significant effect in favour of
treatment (RR 4.02, 95%CI 2.32 to 6.95, P < 0.00001) with neg-
ligible between-study heterogeneity (I2 = 0%, P = 0.99) (Analysis
4.2).
All intracranial haemorrhage during the first 24 hours
Data were available for a total of 202 randomised patients from
two trials (PROACT 1 1998; PROACT 2 1999). There was an
overall highly significant excess risk of intracranial haemorrhage in
the treatment group (RR 3.11, 95% CI 1.56 to 6.18, P = 0.001)
with very little between-study heterogeneity (I2 = 0%, P = 0.46)
(Analysis 5.1).
All intracranial haemorrhage at the end of follow-up
Data were available for a total of 154 randomised patients from
two trials (PROACT11998;MELT2007). Therewas a significant
excess risk of intracerebral haemorrhage in the treatment group
(RR 1.46, 95%CI 1.01 to 2.11, P = 0.04) with very little between-
study heterogeneity (I2 = 0%, P = 0.91) (Analysis 5.2).
Neurological outcome at the end of follow-up
A NIHSS score of 0 to 1 was taken to signify good neurological
outcome. NIHSS data were available for a total of 334 randomised
patients from three trials (PROACT 1 1998; PROACT 2 1999;
MELT 2007). There was a very significant effect in favour of
treatment (RR 2.03, 95% CI 1.21 to 3.40, P = 0.007) with very
little between-study heterogeneity (I2 = 0%, P = 0.65) (Analysis
6.1).
Activities of daily living at the end of follow-up
A Barthel index (BI) score of 90 or greater was taken to signify a
good outcome in terms of activities of daily living. Barthel index
data were available for a total of 334 randomised patients from
three trials (PROACT 1 1998; PROACT 2 1999; MELT 2007).
There was no clear evidence of an effect of treatment on activities
of daily living (RR 1.24, 95% CI 0.94 to1.65, P = 0.13), with very
little between-study heterogeneity (I2 = 0%, P = 0.98) (Analysis
7.1).
Major extracranial haemorrhage in the acute phase
In PROACT 1 1998 two patients had severe injection site haem-
orrhages but the allocation of these patients was unclear. No pa-
tients in MELT 2007 had major extracranial haemorrhages in the
acute phase. It was unclear whether any patients in PROACT 2
1999 or AUST 2005 had major extracranial haemorrhages in the
acute phase.
Subgroup analyses and sensitivity analyses
There were not enough data to perform meaningful subgroup
analyses or sensitivity analyses.
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D I S C U S S I O N
This systematic review acquired data on a comparatively small total
of 350 patients. Most of these data pertain to the effect of intra-
arterial thrombolysis in middle cerebral artery territory strokes,
since mechanical intervention was performed in a minority of
patients randomised to the intervention group in one trial and
posterior circulation strokes affected only a minority of patients.
On the basis of these data, there is evidence that intra-arterial
thrombolytic treatment results in higher rates of recanalisation
than non-thrombolytic standard medical care, and that this effect
translates into significantly improved functional outcome at three-
months follow-up.
These benefits are gained despite a significantly increased rate of all
intracranial haemorrhagewithin 24hours of treatment.While data
for case fatality within the first two weeks following treatment are
too sparse for reliable conclusions to be drawn, it is reassuring that
overall case fatality at the end of follow-up remains unchanged.
Systematic reviews are not immune from bias and a number of
possible sources need to be taken into account. Imbalances in base-
line covariates potentially related to outcome after thrombolysis
can arise through chance in trials with low statistical power. Given
the evidence that women respond more favourably to thrombol-
ysis than men (Kent 2005), the overall excess of women in the
treatment group compared to the control group may have exag-
gerated the overall treatment effect. The excess of diabetic patients
in the PROACT 2 1999 control group would also be expected to
render the treatment group more likely to respond favourably to
thrombolysis (Caso 2007). The trials included in this review were
balanced with respect to other factors associated with improved re-
sponse to thrombolytic treatment (Demchuk 2001; Hacke 2004).
There was no evidence of publication bias. The search delivered
a total of eight published studies, of which only one (PROACT
2 1999) was positive in terms of its primary outcome. While low
statistical power and premature termination affectedmany of these
trials, it is clear that thiswas not a barrier to publication.The ability
to make appropriate use of such data is a strength of systematic
review. Indeed, our meta-analyses benefit from a very low degree
of heterogeneity (I2 = 0), strengthening the likelihood that a single
true effect is being measured in each case.
The applicability of percutaneous vascular interventions is limited
by the particular training and skills required and by the high costs
of the associated drugs, devices and infrastructure. One difficulty
in terms of interpreting these data for the purposes of routine
clinical practice is that pro-urokinase and urokinase are not cur-
rently available. The practice of intra-arterial thrombolysis using
alternative thrombolytic agents such as tissue plasminogen activa-
tor (tPA) relies on non-randomised data (Nedeltchev 2006). Data
from ongoing randomised controlled trials of intra-arterial tPA are
therefore needed in order to definitively establish the role of intra-
arterial thrombolysis in clinical practice, and also to evaluate al-
ternative percutaneous vascular interventions such as mechanical
devices. Further trials are needed comparing percutaneous vascu-
lar interventions with intravenous thrombolytic therapy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current data are insufficient to establish the role of percutaneous
vascular intervention for acute ischaemic stroke in clinical practice.
Implications for research
Data from forthcoming randomised trials will be required in order
to confirm these findings and to establish:
• the effects of various forms of percutaneous vascular
intervention (different thrombolytic drugs, different mechanical
devices);
• the optimal time window for the use of percutaneous
vascular intervention;
• the differential responsiveness of patient subgroups to
percutaneous vascular intervention.
Trials comparing percutaneous vascular interventions to intra-
venous thrombolytic treatment (for example Synthesis Expansion)
are also required.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AUST 2005
Methods Randomised, multicentre, controlled clinical trial
Participants Patients with acute posterior circulation stroke considered to be due to occlusion of
a major vessel were randomised when digital subtraction angiography of the posterior
circulation showed a lesion judged to be lysable
Glasgow Coma Scale ≥ 9
Age 18 to 85 years
Interventions Percutaneous vascular intervention (IA thrombolysis with UK) plus anticoagulation ver-
sus anticoagulation alone, within 24 hours of stroke onset. UK was given in increments
of 100,000IU to amaximum of 1,000,000 IU. All patients received intra-arterial heparin
as a 5000 IU bolus followed by infusion to maintain an APTT of 60 to 80 seconds for
a minimum of 2 days, and then oral warfarin to maintain an INR of 1.5 to 2.5 for 6
months
Outcomes Primary outcome: death or disability (Barthel and Rankin scores) at 6 months
Secondary outcomes: (1) recanalisation rate at 7 to 10 days; (2) neurological impairment
at 6 months; (3) safety and tolerability of IA UK; (4) cost effectiveness of therapy
Notes There was no clear definition of symptomatic intracerebral intracranial haemorrhage
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation by telephone with a central
office, and subsequently by the pharmacy
department at the Royal Melbourne Hos-
pital. In 2 cases patients were randomised
by coin toss in the treating centre, a practice
approved by the trial steering committee.
Concealment of allocation is considered
adequate in each case, but a lack of detail
in relation to the randomisation method-
ology used by the trial sponsor and Royal
MelbourneHospital pharmacy department
means that it remains unclear whether se-
quence generation was satisfactory
Allocation concealment? Yes
Blinding?
All outcomes
Yes All outcomes were determined by an in-
dependent outcomes committee blinded
to treatment allocation. Clinical outcomes
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AUST 2005 (Continued)
were determined at 6 months by a certified
research nurse or a neurologist blinded to
treatment allocation and who was not in-
volved in the patient’s initial care
Incomplete outcome data addressed?
All outcomes
Yes No patients lost to clinical follow-up
Free of selective reporting? No Secondary outcomes not reported
Baseline angiographic findings not re-
ported for 2 patients
No a priori requirement for follow-up
imaging
Free of other bias? Unclear The trial was stopped early because of slow
recruitment and the withdrawal from sale
of UK
MELT 2007
Methods Randomised, controlled, multicentre clinical trial
Participants Acute middle cerebral artery territory ischaemic stroke allowing initiation of treatment
within 6 hours of stroke onset
Patients were randomised when digital subtraction angiography of the symptomatic
carotid artery territory showed complete occlusion of either the horizontal M1 or the
M2 division of the middle cerebral artery
NIHSS at least 5
Age 20 to 75 years
Interventions IA thrombolysis with UK ± mechanical clot disruption with guidewire versus no such
treatment, against a background of standard medical care not including IV-tPA. 5000 IU
heparin were infused prior to introducing the angiogram sheath. The microcatheter was
passed through the clot and UK was infused beyond the distal margin of the thrombus
as repeated boluses of 120,000 IU over 5 minutes to a maximum of 600,000 IU which
were discontinued if complete recanalisation was achieved. Antithrombotic therapies
including heparin, warfarin and aspirin were prohibited for 24 hours after thrombolysis
in the treatment group
Outcomes Primary outcome: favourable clinical outcome, defined as mRS score of 0 to 2 at 3
months
Secondary outcomes: (1) sICH within 24 hours of starting treatment; (2) degree of
recanalisation; (3) NIHSS score 0 to 1 at 24 hours, 30 days, 90 days; (4) Barthel Index
score at least 95 at 30 days, 90 days; (5) mRS score 0 to 1 at 30 days, 90 days; (6) any
haemorrhagic finding on CT
Notes In this study sICH was defined as CT evidence of apparent neurological deterioration
manifesting as either “objective signs” or an increase of at least 4 points from the most
recent NIHSS score. As has been previously pointed out (Saver 2007), the process for
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MELT 2007 (Continued)
adjudicating new “objective signs” is not well delineated and confounds direct compar-
ison with NINDS-defined sICHrates
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation by a central randomisa-
tion centre via the Internet, but the pre-
cise methodology used for randomisation
was not explained and its remains unclear
whether sequence generation was adequate
Allocation concealment? Yes Central randomisation via Internet
Blinding?
All outcomes
Yes All angiograms were evaluated by the film
reading committee, who were unaware of
the clinical information
Clinical outcome was assessed by physi-
cians unaware of the treatment allocation
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat results presented
1 patient not randomised due to computer
error
No patients lost to follow-up
Free of selective reporting? Yes All pre-specified outcomes reported
Free of other bias? Unclear (1) The trial was stopped early by the steer-
ing committee following a recommenda-
tion by the independent monitoring com-
mittee when IV-tPA became available in
Japan. This recommendation was that the
trial be either modified so as not to include
patients presentingwithin 3 hours of stroke
onset, or terminated. This is not considered
to have been a potential source of bias
(2) No information provided regarding
conventional vascular risk factors possibly
related to outcome
PROACT 1 1998
Methods Randomised, controlled, multicentre, phase II clinical trial
Participants Acute middle cerebral artery territory ischaemic stroke allowing initiation of treatment
within 6 hours of stroke onset. Cerebral angiography of the symptomatic carotid artery
territory had to show complete occlusion (TIMI grade 0) or contrast penetration with
minimal perfusion (TIMI grade 1) of either the horizontal M1 or the M2 division of the
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PROACT 1 1998 (Continued)
middle cerebral artery. NIHSS 4 to 30, but patients with isolated aphasia or hemianopia
were also included
Age 18 to 85 years
Interventions IA thrombolysis with pro-UK versus no such treatment against a background of standard
medical care not including IV-tPA. All patients received IV heparin for 4 hours after
angiographic demonstration of an occluding thrombus. The rate of infusion varied
throughout the trial as follows: the first 16 patients received a 100 IU/kg bolus followed
by 1000 IU/hour infusion. On the recommendation of the external safety committee,
the regimen was altered to a 2000 IU bolus followed by 500 IU/hour infusion. Oral
anticoagulants were prohibited for 24 hours following treatment
The PROACT method was to position the microcatheter in the proximal third of the
target clot and thereby to infuse rpro-UK directly into the thrombus over a period of
120 minutes; the entire dose was given irrespective of any recanalisation achieved within
the 120 minute period of infusion. The dose of rpro-UK was 6 mg
Outcomes Primary efficacy outcome: recanalisation of M1 or M2 middle cerebral artery at 120
minutes after initiation of treatment
Primary safety outcome: sICH within 24 hours of treatment. Clinical outcome was
assessed at 7, 30 and 90 days post-treatment (on-treatment analysis)
Notes The protocol for follow-up imaging in this study and PROACT 2 1999 is unclear
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Central randomisation centre assigned pa-
tients to the treatment or control groups,
therefore concealment of allocation is con-
sidered adequate. However, the precise
randomisation methodology was not ex-
plained and it remains unclear whether se-
quence generation was adequate
Allocation concealment? Yes Central randomisation
Blinding?
All outcomes
Yes All investigators and examining physicians
were blinded to treatment assignment
Incomplete outcome data addressed?
All outcomes
No No patients lost to follow-up. This study
did not report the primary efficacy out-
come for 6 randomised but untreated pa-
tients, i.e. an on-treatment rather than
the preferred intention-to-treat analysis.Of
these 6 patients, 5 were in the treatment
group, representing 16% of the total ran-
domised treatment group; the remaining
randomised but untreated patient was in
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PROACT 1 1998 (Continued)
the placebo group. Given the possibility
that the 5 patients randomised to the treat-
ment group who did not receive treatment
represent a subgroup of non-responders,
thismay have had the effect of enriching the
treatment group with responders and bias-
ing the results in favour of treatment. The
primary safety outcome was reported for
these 6 patients, and it is therefore not con-
sidered that the safety analysis is prone to
on-treatment bias. Any on-treatment bias
due to these 6 patients will be diluted in
the overall analysis
Free of selective reporting? Yes All pre-specified outcomes reported
Free of other bias? Unclear (1) No information provided regarding
conventional vascular risk factors possibly
related to outcome
(2) Trial stopped early by sponsor to de-
termine whether there was sufficient evi-
dence of safety and efficacy to support con-
tinuation of a longer term program, ulti-
mately expressed in the form of the phase
III PROACT 2 1999 trial. No safety con-
cerns were involved in that decision. An
analysis of the dataset from all patients who
underwent angiography by a biostatistical
unit independent of the conduct of the trial
forms the basis of the published PROACT
1 1998 report. At the time of termination,
the PROACT 1 1998 trial had achieved
89% of its target sample size. The impli-
cations are difficult to interpret. As a gen-
eral principle, trials which are stopped for
any reason other than according to specific
pre-defined stopping rules are theoretically
prone to bias. However, it is felt that it
remains unclear whether this factor intro-
duced any bias in this particular case
PROACT 2 1999
Methods Randomised, controlled, multicentre, phase III clinical trial
Participants Acute middle cerebral artery territory ischaemic stroke allowing initiation of treatment
within 6 hours of stroke onset. TIMI grade 0 or 1 in either M1 or M2. NIHSS 4 to 30,
or isolated aphasia or hemianopia
Age 18 to 85 years
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PROACT 2 1999 (Continued)
Interventions IA thrombolysis with pro-UK versus no such treatment against a background of standard
medical care not including IV-tPA. See PROACT 1 1998
Outcomes Primary outcome: favourable clinical outcome, defined as a mRS score of 0 to 2 at 3
months
Secondary outcomes: (1)NIHSS 0 to 1 at 90 days; (2) rate of angiographic recanalisation;
(3) at least 50% reduction in baseline NIHSS at 90 days; (4) Barthel Index scores of at
least 60 and at least 90 at 90 days. Clinical outcomes were assessed in a standardised
fashion at 7, 10, 30, and 90 days following randomisation by the same board-certified
or “eligible” neurologist in each centre. All examiners were required to pass certifying
examinations for the NIHSS and Barthel Index, with a requirement for NIHSS re-
certification after approximately 6 months
Notes Published analyses performed independently of the sponsor
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A computer-generated master randomisa-
tion schedule using a randomblock sizewas
used for sequence generation
Allocation concealment? Yes A blinded randomisation codewas assigned
by telephone independent of the sponsor.
The schedule was not stratified by clinical
centre to preclude knowledge of the distri-
bution of future treatment assignments at
a given centre
Blinding?
All outcomes
Yes All CT and 2-hour angiograms were as-
sessed by a neuroradiologist at a core facil-
ity who was blinded to treatment assign-
ment and clinical status. Follow-up exami-
nations were blinded
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat results reported. Some
patients carried forward. Some appropriate
imputation used. No patients lost to fol-
low-up
Free of selective reporting? Yes All pre-specified outcomes reported
Free of other bias? No Significant excess of diabetics in control
group. This is a potential source of bias
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CT: computerised tomography
IA: intra-arterial
IV-tPA: intravenous tissue plasminogen activator
mRS: modified Rankin Scale
NIHSS: National Institutes of Health Stroke Scale
rpro-UK: recombinant pro-urokinase
sICH: symptomatic intracerebral haemorrhage
UK: urokinase
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ducroq 2005 This is not a comparison of IA-tPA versus control, since only the control group is given IV-tPA
Keris 2001 This is not a comparison of IA-tPA versus control, since the intervention group received both IV-tPA and IA-
tPA
Lewandowski 1999 (1) This is not a comparison of IA-tPA versus control (no IA-tPA), since both groups receive IA-tPA
(2) Control group given IA-tPA; this is not the protocol definition of ’routine medical treatment’
Wolfe 2008 (1) This is not a comparison of IA-tPA versus control (no IA-tPA), since both groups receive IA-tPA
(2) Control group given IA-tPA; this is not the protocol definition of ’routine medical treatment’
IA-tPA: intra-arterial tissue plasminogen activator
IV-tPA: intravenous tissue plasminogen activator
Characteristics of ongoing studies [ordered by study ID]
IMS 3
Trial name or title Interventional Management of Stroke (IMS) III Trial
Methods Phase III randomised, multicentre clinical trial
Participants Acute ischaemic stroke, NIHSS at least 10
Age 18 to 80 years
Interventions Patients receive either IV-tPA followed by percutaneous vascular intervention or IV-tPA alone (2:1 ratio). IV-
tPA is given within 3 hours of stroke onset. Percutaneous vascular intervention must begin within 5 hours and
be completed within 7 hours of stroke onset. The choice of percutaneous vascular intervention will be made
by the treating neurointerventionalist from the following options: (1) the Merci thrombus-removal device,
(2) infusion of tPA and delivery of low-intensity ultrasound at the site of the occlusion via the EKOSMicro-
Infusion Catheter, (3) infusion of tPA via a standard micro-catheter
17Percutaneous vascular interventions for acute ischaemic stroke (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
IMS 3 (Continued)
Outcomes Primary efficacy outcome: favourable clinical outcome, defined as a mRS of 0 to 2 at 3 months
Primary safety outcomes: mortality at 3 months and sICH within the first 30 hours after onset
Secondary efficacy measures: (1) Barthel Index, Glasgow Outcome Scale, NIHSSS, EuroQol EQ-5D, and
Trail Making Test, Parts A and B at 3 months; (2) early response to treatment as determined by an NIHSS
of 0 to 2 at 24 hours; (3) a CT angiography assessment of intracranial vascular patency at 24 hours (both
treatment groups); (4) the volume of cerebral infarction as measured by a CT scan at 24 ± 6 hours from
onset; (5) the rate of TICI Grade II or III perfusion flow and recanalisation of the primary arterial occlusion
at completion of angiography (percutaneous vascular intervention group only)
Secondary safety measures: (1) the proportion of participants with Type II parenchymal intracerebral
hematomas within the first 36 hours; (2) the incidence of any asymptomatic haemorrhage within the first 24
hours
Starting date 2006
Contact information Ms Rose Beckmann, Administrative Research Associate
Email: Beckmare@ucmail.uc.edu
Notes 354/900 participants recruited as of February 2010
MR CLEAN
Trial name or title CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands
Methods Phase III randomised, multicentre clinical trial
Minimum age 18 years
Participants Acute ischaemic stroke, NIHSS at least 2
Symptomatic intracranial proximal arterial occlusion demonstrated by CTA, MRA or TCD
Interventions Percutaneous vascular intervention (tPA and/or mechanical thrombectomy) within 6 hours of onset versus
no treatment against a background of optimal medical management including IV-tPA. The choice of percu-
taneous vascular intervention will be made by the treating neurointerventionalist
Outcomes Primary outcome: modified Rankin score at 90 days
Secondary outcomes: (1) vessel recanalisation at 24 to 48 hours after treatment, assessed by CTA orMRA; (2)
infarct size at 24 to 48 hours assessed by CT; (3) asymptomatic or symptomatic intracerebral haemorrhage at
24 to 48 hours assessed by CT
Starting date 2010
Contact information Dr DDippel, ErasmusMedical Center Department of Neurology, Suite Ee 2240a, PO Box 2040, Rotterdam,
The Netherlands
Email: d.dippel@erasmusmc.nl, p.fransen@erasmusmc.nl
Notes
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MR RESCUE
Trial name or title MR Imaging and REcanalisation of Stroke Clots Using Embolectomy
Methods Phase II randomised, multicentre clinical trial
Participants Acute ischaemic stroke, NIHSS at least 6. Large vessel proximal anterior circulation occlusion on MR or CT
angiography (internal carotid, M1 or M2 MCA); percutaneous vascular intervention can be initiated within
8 hours from onset
Age 18 to 85 years
Interventions The Merci thrombus-removal device ± adjunctive tPA versus no treatment against a background of standard
medical care not including IV-tPA
Patients may receive adjunctive tPA after use of the retriever has been completed
Outcomes Primary outcome: modified Rankin score at 90 days
Secondary outcomes: additional clinical, angiographic, and MRI radiographic outcome measures
Starting date 2005
Contact information Ms Gina Ramirez
Email: gcr9@georgetown.edu
Notes 72/120 enrolled as of February 2010
SENTIS
Trial name or title Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke trial
Methods A phase III randomised, multicentre clinical trial
Minimum age 18 years
Participants Acute ischaemic stroke, NIHSS 5 to 18
Percutaneous vascular intervention can be initiated within 14 hours from onset
Interventions NeuroFlo treatment plus standard medical management (American Stroke Association guidelines) versus
standard medical management alone
Outcomes Primary outcomes: efficacy as measured by neurological improvement; and safety as measured by serious
adverse events at 90 days
Secondary Outcomes: (1) acute improvement in neurological function 24 hours post-procedure; (2) hospital
length of stay; (3) patient disposition upon discharge
Starting date 2005
Contact information Ms Lori Austin, VP, Clinical Affairs, CoAxia Inc, 10900 73rd Ave N, Suite 102, Maple Grove, MN 55369,
USA
Notes 500/500 enrolled as of March 2010
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THRACE
Trial name or title Trial and cost-effectiveness evaluation of intra-arterial thrombectomy in acute ischaemic stroke
Methods Randomised multicentre clinical trial
Participants Acute ischaemic stroke, NIHSS 11 to 24
Onset to randomisation within 3 hours
Occlusion of the intracranial carotid, the middle cerebral artery (M1) or the upper third of the basilar artery
Interventions Treatment arm: standard IV thrombolysis alteplase (r-tPA)/Actilyse followed by mechanical thrombectomy
(MERCI, PENUMBRA, CATCH, SOLITAIRE) versus standard IV thrombolysis alone
Outcomes Primary outcome: modified Rankin score at 90 days
Secondary outcomes: quality of life (Euroqol EQ-5D) at 90 days, Barthel Score at 90 days
Starting date 2010
Contact information Principal Investigator: Prof. Serge Bracard, Interventional Neuroradiology, Central Hospital Nancy, France
(HNF)
Email: s.bracard@chu-nancy.fr
Notes
THRUST
Trial name or title THRombectomy in Unsuccessful Stroke Thrombolysis
Methods Randomised multicentre clinical trial
Participants Patients following unsuccessful IV-tPA defined as lack of improvement on the NIHSS after 2 hours compared
with the results immediately before start of treatment
CT angiography must confirm a retrievable occlusion
Age range not available
Interventions Thrombectomy using the MERCI thrombus-removal device versus no intervention
Outcomes No data currently available
Starting date No data currently available
Contact information SITS (Safe Implementation of Thrombolysis in Stroke) International, Karolinska Stroke Research, Depart-
ment of Neurology, R2:03, Karolinska University Hospital, S-171 76 Stockholm, Sweden
Email:sits.ico@acutestroke.org
Notes
CT: computerised tomography
CTA: computed tomography angiography
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IV: intravenous
IV-tPA: intravenous tissue plasminogen activator
MCA: middle cerebral artery
MRA:magnetic resonance angiography
MRI: magnetic resonance imaging
mRS: modified Rankin Scale
NIHSS: National Institutes of Health Stroke Scale
r-tPA: recombinant tissue plasminogen activator
sICH: symptomatic intracerebral haemorrhage
TCD: transcranial doppler
tPA: tissue plasminogen activator
21Percutaneous vascular interventions for acute ischaemic stroke (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Functional outcome at end of follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Functional outcome: mRS 0 to 2 3 310 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.07, 2.02]
2 Functional outcome: mRS 0 to 1 4 350 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [1.17, 2.57]
Comparison 2. Case fatality (all cause)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Case fatality at end of follow-up 4 350 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.60, 1.33]
2 Case fatality within acute phase
(first 2 weeks)
1 114 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.25, 101.89]
Comparison 3. Symptomatic intracranial haemorrhage (NINDS)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic intracranial
haemorrhage within 24 hours
2 202 Risk Ratio (M-H, Fixed, 95% CI) 3.85 [0.91, 16.36]
2 Symptomatic intracranial
haemorrhage at the end of
follow-up
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.22, 5.17]
Comparison 4. Recanalisation rate at 120 minutes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recanalisation: TIMI grade 3 2 198 Risk Ratio (M-H, Fixed, 95% CI) 8.25 [1.63, 41.90]
2 Recanalisation: TIMI grade 2
and 3
2 198 Risk Ratio (M-H, Fixed, 95% CI) 4.02 [2.32, 6.95]
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Comparison 5. All intracranial haemorrhages
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All intracranial haemorrhages
within 24 hours
2 202 Risk Ratio (M-H, Fixed, 95% CI) 3.11 [1.56, 6.18]
2 All intracranial haemorrhages at
the end of follow-up
2 154 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.01, 2.11]
Comparison 6. Good neurological outcome (NIHSS 0 to 1) at end of follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Good neurological outcome
(NIHSS 0 to 1) at the end of
follow-up
3 334 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [1.21, 3.40]
Comparison 7. Barthel Index at end of follow-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Barthel Index at least 90 at end
of follow-up
3 334 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.94, 1.65]
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Analysis 1.1. Comparison 1 Functional outcome at end of follow-up, Outcome 1 Functional outcome: mRS
0 to 2.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 1 Functional outcome at end of follow-up
Outcome: 1 Functional outcome: mRS 0 to 2
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AUST 2005 4/8 1/8 2.3 % 4.00 [ 0.56, 28.40 ]
MELT 2007 28/57 22/57 51.0 % 1.27 [ 0.84, 1.94 ]
PROACT 2 1999 48/121 15/59 46.7 % 1.56 [ 0.96, 2.54 ]
Total (95% CI) 186 124 100.0 % 1.47 [ 1.07, 2.02 ]
Total events: 80 (Experimental), 38 (Control)
Heterogeneity: Chi2 = 1.51, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 1.2. Comparison 1 Functional outcome at end of follow-up, Outcome 2 Functional outcome: mRS
0 to 1.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 1 Functional outcome at end of follow-up
Outcome: 2 Functional outcome: mRS 0 to 1
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AUST 2005 3/8 0/8 1.6 % 7.00 [ 0.42, 116.91 ]
MELT 2007 24/57 13/57 42.1 % 1.85 [ 1.05, 3.25 ]
PROACT 1 1998 8/26 3/14 12.6 % 1.44 [ 0.45, 4.57 ]
PROACT 2 1999 31/121 10/59 43.6 % 1.51 [ 0.80, 2.87 ]
Total (95% CI) 212 138 100.0 % 1.73 [ 1.17, 2.57 ]
Total events: 66 (Experimental), 26 (Control)
Heterogeneity: Chi2 = 1.27, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0063)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 2.1. Comparison 2 Case fatality (all cause), Outcome 1 Case fatality at end of follow-up.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 2 Case fatality (all cause)
Outcome: 1 Case fatality at end of follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
AUST 2005 4/8 4/8 11.3 % 1.00 [ 0.38, 2.66 ]
MELT 2007 3/57 2/57 5.7 % 1.50 [ 0.26, 8.64 ]
PROACT 1 1998 7/26 6/14 22.1 % 0.63 [ 0.26, 1.51 ]
PROACT 2 1999 30/121 16/59 60.9 % 0.91 [ 0.54, 1.54 ]
Total (95% CI) 212 138 100.0 % 0.89 [ 0.60, 1.33 ]
Total events: 44 (Experimental), 28 (Control)
Heterogeneity: Chi2 = 1.02, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
Analysis 2.2. Comparison 2 Case fatality (all cause), Outcome 2 Case fatality within acute phase (first 2
weeks).
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 2 Case fatality (all cause)
Outcome: 2 Case fatality within acute phase (first 2 weeks)
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MELT 2007 2/57 0/57 100.0 % 5.00 [ 0.25, 101.89 ]
Total (95% CI) 57 57 100.0 % 5.00 [ 0.25, 101.89 ]
Total events: 2 (Experimental), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 3.1. Comparison 3 Symptomatic intracranial haemorrhage (NINDS), Outcome 1 Symptomatic
intracranial haemorrhage within 24 hours.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 3 Symptomatic intracranial haemorrhage (NINDS)
Outcome: 1 Symptomatic intracranial haemorrhage within 24 hours
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PROACT 1 1998 4/26 1/14 49.4 % 2.15 [ 0.27, 17.46 ]
PROACT 2 1999 11/108 1/54 50.6 % 5.50 [ 0.73, 41.50 ]
Total (95% CI) 134 68 100.0 % 3.85 [ 0.91, 16.36 ]
Total events: 15 (Experimental), 2 (Control)
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 3.2. Comparison 3 Symptomatic intracranial haemorrhage (NINDS), Outcome 2 Symptomatic
intracranial haemorrhage at the end of follow-up.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 3 Symptomatic intracranial haemorrhage (NINDS)
Outcome: 2 Symptomatic intracranial haemorrhage at the end of follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PROACT 1 1998 4/26 2/14 100.0 % 1.08 [ 0.22, 5.17 ]
Total (95% CI) 26 14 100.0 % 1.08 [ 0.22, 5.17 ]
Total events: 4 (Experimental), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
Analysis 4.1. Comparison 4 Recanalisation rate at 120 minutes, Outcome 1 Recanalisation: TIMI grade 3.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 4 Recanalisation rate at 120 minutes
Outcome: 1 Recanalisation: TIMI grade 3
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PROACT 1 1998 5/26 0/14 32.0 % 6.11 [ 0.36, 103.08 ]
PROACT 2 1999 20/108 1/50 68.0 % 9.26 [ 1.28, 67.07 ]
Total (95% CI) 134 64 100.0 % 8.25 [ 1.63, 41.90 ]
Total events: 25 (Experimental), 1 (Control)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 4.2. Comparison 4 Recanalisation rate at 120 minutes, Outcome 2 Recanalisation: TIMI grade 2
and 3.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 4 Recanalisation rate at 120 minutes
Outcome: 2 Recanalisation: TIMI grade 2 and 3
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PROACT 1 1998 15/26 2/14 17.4 % 4.04 [ 1.07, 15.19 ]
PROACT 2 1999 78/108 9/50 82.6 % 4.01 [ 2.20, 7.33 ]
Total (95% CI) 134 64 100.0 % 4.02 [ 2.32, 6.95 ]
Total events: 93 (Experimental), 11 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.97 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
Analysis 5.1. Comparison 5 All intracranial haemorrhages, Outcome 1 All intracranial haemorrhages
within 24 hours.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 5 All intracranial haemorrhages
Outcome: 1 All intracranial haemorrhages within 24 hours
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
PROACT 1 1998 11/26 1/14 12.2 % 5.92 [ 0.85, 41.27 ]
PROACT 2 1999 38/108 7/54 87.8 % 2.71 [ 1.30, 5.67 ]
Total (95% CI) 134 68 100.0 % 3.11 [ 1.56, 6.18 ]
Total events: 49 (Experimental), 8 (Control)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 3.23 (P = 0.0012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 5.2. Comparison 5 All intracranial haemorrhages, Outcome 2 All intracranial haemorrhages at the
end of follow-up.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 5 All intracranial haemorrhages
Outcome: 2 All intracranial haemorrhages at the end of follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MELT 2007 31/57 21/57 76.4 % 1.48 [ 0.97, 2.24 ]
PROACT 1 1998 13/26 5/14 23.6 % 1.40 [ 0.63, 3.12 ]
Total (95% CI) 83 71 100.0 % 1.46 [ 1.01, 2.11 ]
Total events: 44 (Experimental), 26 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.045)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 6.1. Comparison 6 Good neurological outcome (NIHSS 0 to 1) at end of follow-up, Outcome 1
Good neurological outcome (NIHSS 0 to 1) at the end of follow-up.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 6 Good neurological outcome (NIHSS 0 to 1) at end of follow-up
Outcome: 1 Good neurological outcome (NIHSS 0 to 1) at the end of follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MELT 2007 20/57 8/57 42.8 % 2.50 [ 1.20, 5.20 ]
PROACT 1 1998 5/26 1/14 6.9 % 2.69 [ 0.35, 20.84 ]
PROACT 2 1999 22/121 7/59 50.3 % 1.53 [ 0.69, 3.38 ]
Total (95% CI) 204 130 100.0 % 2.03 [ 1.21, 3.40 ]
Total events: 47 (Experimental), 16 (Control)
Heterogeneity: Chi2 = 0.87, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0075)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
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Analysis 7.1. Comparison 7 Barthel Index at end of follow-up, Outcome 1 Barthel Index at least 90 at end of
follow-up.
Review: Percutaneous vascular interventions for acute ischaemic stroke
Comparison: 7 Barthel Index at end of follow-up
Outcome: 1 Barthel Index at least 90 at end of follow-up
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
MELT 2007 28/57 23/57 41.8 % 1.22 [ 0.81, 1.84 ]
PROACT 1 1998 11/26 5/14 11.8 % 1.18 [ 0.51, 2.73 ]
PROACT 2 1999 50/121 19/59 46.4 % 1.28 [ 0.84, 1.97 ]
Total (95% CI) 204 130 100.0 % 1.24 [ 0.94, 1.65 ]
Total events: 89 (Experimental), 47 (Control)
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours experimental
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
The following search strategy was used for MEDLINE (Ovid) and modified for other databases.
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid artery diseases/ or carotid artery
thrombosis/ or intracranial arterial diseases/ or cerebral arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp stroke/
2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. 1 or 2 or 3
5. radiography, interventional/ or radiology, interventional/
6. catheterization/ or angioplasty/ or angioplasty, balloon/ or angioplasty, balloon, laser-assisted/ or angioplasty, laser/ or atherectomy/
or balloon dilatation/ or catheter ablation/
7. stents/
8. thrombectomy/ or embolectomy/
9. blood vessel prosthesis/ or blood vessel prosthesis implantation/
10. cerebral revascularization/ or reperfusion/ or dilatation/
11. (interventional adj3 (radiolog$ or radiograph$ or neuroradiolog$)).tw.
12. (angioplast$ or stent$).tw.
13. (thrombectomy or thromboaspiration or embolectomy or atherect$).tw.
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14. sonothrombolysis.tw.
15. ((mechanical or radiolog$ or pharmacomechanical or laser or endovascular or neurovascular) adj5 (thrombolys$ or reperfusion or
fragmentation or aspiration or recanali?ation or clot lys$)).tw.
16. ((clot or thrombus or thrombi or embol$) adj5 (aspirat$ or remov$ or retriev$ or fragmentation or retract$ or extract$ or obliterat$
or dispers$)).tw.
17. ((retrieval or extraction) adj5 device$).tw.
18. endoluminal repair$.tw.
19. (blood vessel adj5 (prosthesis or implantat$)).tw.
20. ((merci or concentric) adj retriever).tw.
21. (endovascular snare$ or neuronet or microsnare or X-ciser or angiojet).tw.
22. or/5-21
23. 4 and 22
24. limit 23 to humans
25. Randomized Controlled Trials as Topic/
26. random allocation/
27. Controlled Clinical Trials as Topic/
28. control groups/
29. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
30. double-blind method/
31. single-blind method/
32. Therapies, Investigational/
33. randomized controlled trial.pt.
34. controlled clinical trial.pt.
35. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
36. random$.tw.
37. (controlled adj5 (trial$ or stud$)).tw.
38. (clinical$ adj5 trial$).tw.
39. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
40. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
41. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
42. (coin adj5 (flip or flipped or toss$)).tw.
43. or/25-42
44. 24 and 43
Appendix 2. EMBASE search strategy
1. cerebrovascular disease/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar insufficiency/ or carotid
artery disease/ or exp carotid artery obstruction/ or exp brain infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/
or stroke patient/ or stroke unit/
2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or
middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. 1 or 2 or 3
5. interventional radiology/ or endovascular surgery/
6. percutaneous transluminal angioplasty/ or angioplasty/ or laser angioplasty/ or catheterization/ or catheter ablation/ or balloon
dilatation/ or exp atherectomy/
7. stent/
8. thrombectomy/ or exp percutaneous thrombectomy/ or embolectomy/
9. artery prosthesis/
10. cerebral revascularization/ or reperfusion/ or artery dilatation/ or recanalization/
11. (interventional adj3 (radiolog$ or radiograph$ or neuroradiolog$)).tw.
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12. (angioplast$ or stent$).tw.
13. (thrombectomy or embolectomy or atherect$).tw.
14. thromboaspiration.tw.
15. ((mechanical or radiolog$ or pharmacomechanical or laser or endovascular or neurovascular) adj5 (thrombolys$ or reperfusion or
fragmentation or aspiration or recanali?ation or clot lys$)).tw.
16. ((clot or thrombus or thrombi or embol$) adj5 (aspirat$ or remov$ or retriev$ or fragmentation or retract$ or extract$ or obliterat$
or dispers$)).tw.
17. ((retrieval or extraction) adj5 device$).tw.
18. endoluminal repair$.tw.
19. ((blood vessel or artery) adj5 (prosthesis or implantat$)).tw.
20. ((merci or concentric) adj retriever).tw.
21. (endovascular snare$ or neuronet or microsnare or X-ciser or angiojet).tw.
22. ultrasound/ or exp ultrasound therapy/ or echography/ or doppler echography/ or intravascular ultrasound/
23. (ultrasound$ or ultrasonic$ or ultrasonogra$ or sonograph$ or insonation).tw.
24. ((transcranial adj5 doppler) or TCD or TCCD).tw.
25. fibrinolytic therapy/
26. fibrinolytic agent/ or plasmin/ or plasminogen/ or exp plasminogen activator/
27. blood clot lysis/
28. fibrinolysis/
29. (thromboly$ or fibrinoly$ or recanalis$ or recanaliz$ or sonolys$).tw.
30. ((clot$ or thrombus) adj5 (lyse or lysis or dissolve$ or dissolution or fragment$)).tw.
31. (tPA or t-PA or rtPA or rt-PA or plasminogen or plasmin or alteplase or actilyse).tw.
32. (anistreplase or streptodornase or streptokinase or urokinase or pro?urokinase or rpro?uk or lumbrokinase or duteplase or lanoteplase
or pamiteplase or reteplase or saruplase or staphylokinase or streptase).tw.
33. (sonothrombolysis or sonothromboly$ or sonothrombotripsy or thrombotripsy).tw.
34. or/22-33
35. intraarterial drug administration/
36. (intra arterial or intra-arterial or intraarterial or IA).tw.
37. 35 or 36
38. 34 and 37
39. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 38
40. 4 and 39
41. Randomized Controlled Trial/
42. Randomization/
43. Controlled Study/
44. control group/
45. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical
trial/
46. Double Blind Procedure/
47. Single Blind Procedure/ or triple blind procedure/
48. random$.tw.
49. (controlled adj5 (trial$ or stud$)).tw.
50. (clinical$ adj5 trial$).tw.
51. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
52. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
53. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
54. (coin adj5 (flip or flipped or toss$)).tw.
55. or/41-54
56. 40 and 55
57. limit 56 to human
58. (carotid or hemorrhag$ or haemorrhag$ or aneurysm$ or fibrillation or trauma$ or aort$ or coronary or myocardial).ti.
59. 57 not 58
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol specified that percutaneous vascular intervention in the form of sonothrombolysis would be eligible for inclusion.
Following discussion, it was clarified that sonothrombolysis would only be eligible for inclusion when delivered by intravascular means.
The list of outcomes has been altered as follows.
1. Deaths attributable to stroke has been removed as an outcome.
2. Neurological outcome as measured by the National Institutes of Health Stroke Scale has been added.
3. Functional outcome as measured by the Barthel Index has been added.
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Medical Subject Headings (MeSH)
Brain Ischemia [drug therapy; ∗therapy]; Catheterization [∗methods]; Fibrinolytic Agents [∗administration & dosage]; Infarction,
Middle Cerebral Artery [therapy]; Intracranial Hemorrhages [etiology]; Randomized Controlled Trials as Topic; Recombinant Proteins
[administration & dosage]; Urokinase-Type Plasminogen Activator [administration & dosage]
MeSH check words
Aged; Female; Humans; Male; Middle Aged
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